Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. End-use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. End-use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Wound Contact Layer Dressing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Increasing prevalence of chronic diseases impacting wound healing capabilities
3.3.1.2. Rising number of accidents
3.3.1.3. Increase in number of healthcare centers such as ASCs
3.3.2. Market restraint analysis
3.3.2.1. High cost of advanced wound care products
3.4. Wound Contact Layer Dressing Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PEST Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic landscape
3.4.2.3. Social landscape
3.4.2.4. Technological landscape
Chapter 4. Wound Contact Layer Dressing Market: Product Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Antimicrobial
4.1.2. Non-antimicrobial
4.2. Product Market Share, 2022 & 2030
4.3. Segment Dashboard
4.4. Wound Contact Layer Dressing Market by Product Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5.1. Antimicrobial
4.5.1.1. Antimicrobial market estimates and forecast 2018 to 2030 (USD Million)
4.5.2. Non-antimicrobial
4.5.2.1. Non-antimicrobial market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Wound Contact Layer Dressing Market: End-user Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Hospitals
5.1.2. Outpatient
5.1.3. Home Healthcare
5.1.4. Research & Manufacturing
5.2. End-user Market Share, 2022 & 2030
5.3. Segment Dashboard
5.4. Wound Contact Layer Dressing Market by End-user Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5.1. Hospitals
5.5.1.1. Hospitals market estimates and forecast 2018 to 2030, (USD Million)
5.5.2. Outpatient
5.5.2.1. Outpatient market estimates and forecast 2018 to 2030 (USD Million)
5.5.3. Home Healthcare
5.5.3.1. Outpatient market estimates and forecast 2018 to 2030 (USD Million)
5.5.4. Research & Manufacturing
5.5.4.1. Outpatient market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Wound Contact Layer Dressing Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2022 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Regional Market Share and Leading Players, 2022
6.4.1. North America
6.4.2. Europe
6.4.3. Asia Pacific
6.4.4. Latin America
6.4.5. Middle East and Africa
6.5. Market Estimate & Forecasts and Trend Analysis, 2018 to 2030
6.6. North America
6.6.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.6.2. U.S.
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework
6.6.2.3. Reimbursement scenario
6.6.2.4. U.S. market estimates and forecasts, 2018 – 2030
6.6.3. Canada
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework
6.6.3.3. Reimbursement scenario
6.6.3.4. Canada market estimates and forecasts, 2018 – 2030
6.7. Europe
6.7.1. UK
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework
6.7.1.3. Reimbursement scenario
6.7.1.4. UK market estimates and forecasts, 2018 – 2030
6.7.2. Germany
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework
6.7.2.3. Reimbursement scenario
6.7.2.4. Germany market estimates and forecasts, 2018 – 2030
6.7.3. France
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework
6.7.3.3. Reimbursement scenario
6.7.3.4. France market estimates and forecasts, 2018 – 2030
6.7.4. Italy
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework
6.7.4.3. Reimbursement scenario
6.7.4.4. Italy market estimates and forecasts, 2018 – 2030
6.7.5. Spain
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework
6.7.5.3. Reimbursement scenario
6.7.5.4. Spain market estimates and forecasts, 2018 – 2030
6.7.6. Denmark
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework
6.7.6.3. Reimbursement scenario
6.7.6.4. Denmark market estimates and forecasts, 2018 – 2030
6.7.7. Sweden
6.7.7.1. Key country dynamics
6.7.7.2. Regulatory framework
6.7.7.3. Reimbursement scenario
6.7.7.4. Sweden market estimates and forecasts, 2018 – 2030
6.7.8. Norway
6.7.8.1. Key country dynamics
6.7.8.2. Regulatory framework
6.7.8.3. Reimbursement scenario
6.7.8.4. Norway market estimates and forecasts, 2018 – 2030
6.8. Asia Pacific
6.8.1. Japan
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework
6.8.1.3. Reimbursement scenario
6.8.1.4. Japan market estimates and forecasts, 2018 – 2030
6.8.2. India
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework
6.8.2.3. Reimbursement scenario
6.8.2.4. India market estimates and forecasts, 2018 – 2030
6.8.3. China
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework
6.8.3.3. Reimbursement scenario
6.8.3.4. China market estimates and forecasts, 2018 – 2030
6.8.4. South Korea
6.8.4.1. Key country dynamics
6.8.4.2. Regulatory framework
6.8.4.3. Reimbursement scenario
6.8.4.4. South Korea market estimates and forecasts, 2018 – 2030
6.8.5. Australia
6.8.5.1. Key country dynamics
6.8.5.2. Regulatory framework
6.8.5.3. Reimbursement scenario
6.8.5.4. Australia market estimates and forecasts, 2018 – 2030
6.8.6. Thailand
6.8.6.1. Key country dynamics
6.8.6.2. Regulatory framework
6.8.6.3. Reimbursement scenario
6.8.6.4. Thailand market estimates and forecasts, 2018 – 2030
6.9. Latin America
6.9.1. Brazil
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework
6.9.1.3. Reimbursement scenario
6.9.1.4. Brazil market estimates and forecasts, 2018 – 2030
6.9.2. Mexico
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework
6.9.2.3. Reimbursement scenario
6.9.2.4. Mexico market estimates and forecasts, 2018 – 2030
6.9.3. Argentina
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework
6.9.3.3. Reimbursement scenario
6.9.3.4. Argentina market estimates and forecasts, 2018 – 2030
6.10. MEA
6.10.1. South Africa
6.10.1.1. Key country dynamics
6.10.1.2. Regulatory framework
6.10.1.3. Reimbursement scenario
6.10.1.4. South Africa market estimates and forecasts, 2018 – 2030
6.10.2. Saudi Arabia
6.10.2.1. Key country dynamics
6.10.2.2. Regulatory framework
6.10.2.3. Reimbursement scenario
6.10.2.4. Saudi Arabia market estimates and forecasts, 2018 – 2030
6.10.3. UAE
6.10.3.1. Key country dynamics
6.10.3.2. Regulatory framework
6.10.3.3. Reimbursement scenario
6.10.3.4. UAE market estimates and forecasts, 2018 – 2030
6.10.4. Kuwait
6.10.4.1. Key country dynamics
6.10.4.2. Regulatory framework
6.10.4.3. Reimbursement scenario
6.10.4.4. Kuwait market estimates and forecasts, 2018 – 2030
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.1.1. Innovators
7.2. Vendor Landscape
7.2.1. List of key distributors and channel partners
7.2.2. Key customers
7.2.3. Key company market share analysis, 2022
7.2.4. Hollister Incorporated
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. 3M
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Cardinal Health
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Advanced Medical Solutions Limited
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Avery Dennison Corporation
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Elkem ASA
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Paul Hartmann
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. BSN Medical
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Smith + Nephew
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Medline Industries
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. Molnlycke Health Care
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
